992
Index
Protozoal infections
continued
care considerations, 174
contraindications and cautions,
172–173
drug–drug interactions, 173–174
pharmacokinetics, 172
therapeutic actions and indications,
172
amoebiasis, 163, 170–171
care considerations, 174
cinchonism, 163
giardiasis, 163, 172
leishmaniasis, 163, 171
Pneumocystis carinii
pneumonia, 163,
172
trichomoniasis, 163, 172
trypanosomiasis, 163, 172
Proxymetacaine hydrochloride, 958
Prozac, 327
Pseudoephedrine, 842, 847–849
Psychological factors
drug effects and, 25, 27
Psychotherapeutic agents, 334–350
adults, 335
antimanic drugs, 344–347
adverse effects, 345
care considerations (persons receiving
lithium), 346–347
contraindications and cautions,
344–345
drug–drug interactions, 345–346
pharmacokinetics, 344
therapeutic actions and indications,
344
antipsychotic/neuroleptic drugs, 334,
336–342
adverse effects, 341
care considerations, 342
contraindications and cautions, 340
critical thinking scenario, 343–344
cultural considerations, 340
drug–drug interactions, 341
pharmacokinetics, 339
therapeutic actions and indications,
339
central nervous system stimulants,
347–348
adverse effects, 348
care considerations, 348–349
contraindications and cautions, 348
drug–drug interactions, 348
pharmacokinetics, 348
therapeutic actions and indications,
348
children, 335
cultural considerations, 340
mental disorders and their classification,
335–336
older adults, 335, 340
Psyllium, 346, 688, 917, 919, 920, 966
Puberty, 596, 598
Pulmonary arterial hypertension, 664
Pulmonary circulation, 649–650
Pulmonary disorders.
See
Lower
respiratory tract, drugs acting on
Pulmonary oedema, 681, 683
Pulse pressure, 642, 651, 713, 714
PVCs (premature ventricular
contractions), 696, 699, 700
Pyelonephritis, 819, 820
Pyramidal tract, 385, 387
Pyrantel, 183, 185, 186
Pyridostigmine, 487, 489, 493–495
Pyrimethamine, 172–174
Pyrogen, 229
Q
Q fever, 279
Quality Use of Medicines (QUM)
program, 65
Quetiapine, 336, 338, 344, 345
Quinagolide, 526
Quinapril, 662, 665
Quinidine, 704, 706, 707
Quinine, 167
R
Rabeprazole, 900, 906–907
Rabies immunoglobulin, 286
Rabies vaccine, 281
Raloxifene, 606, 609, 614, 615
Raltegravir, 127, 137, 141–142
Raltitrexed, 200, 202
Ramipril, 662, 665
Ranitidine, 897, 900–903
RAS (reticular activating system), 298,
336, 347
Rasagiline, 382
Rasburicase, 198
Rashes, 33–34
Raspberry, 966
Reabsorption, 794, 797
Rebound congestion, 842, 846
Reboxetine, 331
Receptor response
loss of, 17–18
Receptor sites, 16, 17
Receptor theory of drug action, 17–18
Recombinant DNA technology, 258, 259
Red blood cell production, 799–800
Red clover, 613, 966
Red yeast rice, 966
Reference books, 11–12
Reflexes, gastrointestinal, 892–894
central, 893–894
local, 888, 892–893
Releasing factors, 514
Releasing hormones, 514
Remifentanil, 402
Renal system, 794–800
diuretics.
See
Diuretic agents
kidneys.
See
Kidneys
renal injury, 36
urinary tract.
See
Urinary tract
Renin–angiotensin–aldosterone system,
652, 653, 657, 659, 794, 799
Repolarisation, 292, 294
Reproductive system, 596–604
female, 597–601
hormones, 598–599
menopause, 601
menstrual cycle, 599–600
pregnancy, 8–9, 600–601
structures, 597–598
human sexual response, 603–604
male, 602–603
hormones, 601–603
structures, 602, 602
Reproductive system, female, drugs
affecting, 606–624
adults, 608
children, 608
fertility drugs, 617–620
oestrogen receptor modulators,
614–616
care considerations, 615–616
older adults, 608
sex hormones, 607–614
care considerations, 615–616
uterine motility drugs, 620–624
oxytocics, 620–622
prostaglandins, 620, 622–624
Reproductive system, male, drugs
affecting, 627–638
adults, 629
anabolic steroids, 627, 631–634
androgens, 627, 628–631
children, 629
drug–food interactions, 636
older adults, 629
penile erectile dysfunction, 627,
634–637
Resistance, 81, 84–85
acquiring, 84
bacterial, 84
preventing, 85
system, 642, 650
Respiration, 834, 836
Respiratory distress syndrome (RDS),
834, 839–840
Respiratory membrane, 834, 836, 837
Respiratory system, 834–840
fixed combination drugs, 877
lower respiratory tract, drugs acting on.
See
Lower respiratory tract, drugs
acting on
obstructive pulmonary disorders.
See
Pulmonary disorders, drugs used
to treat
pathophysiology, 837–840
lower respiratory tract conditions,
838–840
upper respiratory tract conditions,
837–838
structure and function, 835–837
gas exchange, 836–837
respiration, 837
upper respiratory tract, drugs acting on.
See
Upper respiratory tract, drugs
acting on
Respiratory viruses.
See
Influenza A and
respiratory viruses, drugs for
Retaplase, 757, 764
Reticular activating system (RAS).
See
RAS (reticular activating system)
Reticulocyte, 774, 775
Rheumatoid arthritis, 241, 243, 244–245
Rhinitis medicamentosa, 842, 846
